Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

37.41 -0.35 (-0.93%)
Streaming Delayed Price Updated: 10:21 AM EST, Nov 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
28 29 Next >
News headline image
3 Stocks That Could Be Monster Winners in 2025 ↗
Via The Motley Fool
News headline image
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck? ↗
Via The Motley Fool
News headline image
My Top 10 Stocks to Buy for 2025 ↗
Via The Motley Fool
News headline image
Why Viking Therapeutics Tumbled by More Than 10% This Week ↗
Via The Motley Fool
News headline image
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up ↗
Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for. 
Via The Motley Fool
News headline image
Looking Into Viking Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Viking Therapeutics? ↗
 
Via Benzinga
News headline image
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review ↗
Micron, Vertex, Novo Nordisk and Nike were notable losers on news. 
Via Investor's Business Daily
Topics Economy
News headline image
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump. ↗
Eli Lilly and Viking Therapeutics jumped on Novo's setback. 
Via Investor's Business Daily
News headline image
From Powell To Profits: Strategic Stock Picks Amid Market Uncertainty ↗
Yesterday's market movement aligned perfectly with expectations, as the FOMC meeting drove significant volatility. 
Via Talk Markets
Topics Stocks / Equities
News headline image
What's Going On With Viking Therapeutics Stock On Wednesday? ↗
Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for future growth. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
News headline image
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030 ↗
Via The Motley Fool
News headline image
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street ↗
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Via The Motley Fool
News headline image
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗
Via The Motley Fool
News headline image
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now? ↗
Via The Motley Fool
News headline image
2 Disruptive Growth Stocks With Room to Run ↗
Via The Motley Fool
News headline image
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum ↗
Analysts are concerned about Viking's ability to compete in the lucrative obesity drug market, dominated by Eli Lilly and Novo Nordisk. 
Via Benzinga
News headline image
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow ↗
Via The Motley Fool
News headline image
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs ↗
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis. 
Via Benzinga
News headline image
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst ↗
Via The Motley Fool
News headline image
3 Monster Stocks in the Making ↗
Via The Motley Fool
News headline image
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry? ↗
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS